DRAXIN (dorsal inhibitory axon guidance protein) is a chemorepulsive guidance molecule essential for central nervous system development. Structurally, DRAXIN interacts with multiple netrin receptors including DCC (deleted in colorectal cancer), UNC5 homologs, Neogenin, and DSCAM 1. DRAXIN binds DCC with subnanomolar affinity at a region distinct from the netrin-binding domain 1, and can capture and tether netrin-1 to DCC receptors through its EGF-3 domain, regulating axon fasciculation and guidance 2. During development, DRAXIN mediates repulsion of commissural axons and is critical for forebrain and spinal cord commissure formation 13. Beyond axon guidance, DRAXIN inhibits neural crest cell delamination and migration by increasing cell adhesion through vinculin expression 4. Disease relevance emerged recently: high DRAXIN expression in glioma tissue correlates with poor patient prognosis and serves as an independent risk factor 5. In vitro, DRAXIN knockdown significantly inhibited glioma cell proliferation and invasion 5. DRAXIN also participates in cortical neuronal migration regulation 6. These findings suggest DRAXIN has dual roles as a developmental guidance molecule and potential oncogenic factor, warranting investigation as both a prognostic biomarker and therapeutic target in glioma.